Aptar Pharma, the leading manufacturer of drug delivery systems for nasal applications worldwide, announces the installation of manufacturing capacity for its Child-Resistant and Senior-Friendly Classic Nasal Pump in their Congers (NY, USA) site.
Effective April 2017, a new assembly machine for Aptar Pharma’s Child-Resistant (CR) feature for nasal sprays was transferred from Aptar Pharma’s plant in Southern Germany to Congers, NY. This represents an important step in Aptar Pharma’s history, bringing its manufacturing capacity closer to the target market, for which this pump has been successfully established.
Aptar Pharma’s Child-Resistant technology platform was developed primarily for the US market when, in 2012, the US Consumer Product Safety Commission (CPSC) issued a rule requiring Child-Resistant packaging for any over-the-counter or drug product containing the equivalent of 0.08 mg or more of imidazoline (16 CFR Part 1700.14), a formulation widely used in nasal decongestant topical sprays.
Less than 2 years after the rule’s announcement, Aptar Pharma introduced its newly engineered Child-Resistant/Senior-Friendly nasal spray pump to the US market, which successfully matched the CPSC requirements. This feat once more underscored Aptar Pharma’s worldwide reputation as an innovative leader and trusted partner in the pharmaceutical industry.
Aptar Pharma’s Child-Resistant Feature for nasal sprays effectively combines Child-Resistance (CR) and Senior-Friendliness (SF) with its intuitive and widely accepted squeeze-and-turn technology. The positive market feedback and increasing demand for the Child-Resistant Feature during the last 2 years demonstrates that Aptar Pharma’s CRSF technology is the best-in-class solution available on the US market.
As of today, all major brands of nasal decongestant topical sprays in the US come with Aptar Pharma’s Child-Resistant Feature.
According to Alex Theodorakis, President Aptar Pharma North America: “We are pleased to welcome the arrival of Aptar Pharma’s Child-Resistant assembly machine to our recently-expanded Congers, NY manufacturing site. This added manufacturing capacity enables us to offer the production of this key Child-Resistant/Senior-Friendly feature to our customers domestically.”
“Being closer to our customers continues to be of strategic importance to Aptar Pharma, and this new initiative enables us to continue to support our important North American marketplace and increase our demand reactivity.”